01—Abstract
Summary
Summary of the 8-K filed March 21, 2025. Cited figures are marked; the original filing is the authoritative source.
On March 20, 2025, Alnylam Pharmaceuticals (Nasdaq: ALNY) announced that the U.S. FDA approved a supplemental New Drug Application for AMVUTTRA (vutrisiran) to treat the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, reducing cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.
The approval is a significant commercial and clinical milestone: AMVUTTRA becomes the first and only FDA-approved therapy for both ATTR-CM and hATTR polyneuropathy (hATTR-PN), substantially expanding its addressable U.S. market. The company estimates ATTR-CM affects roughly 150,000 people in the U.S. and over 300,000 worldwide, a population that is largely undiagnosed and untreated, which suggests a large opportunity for growth. The approval is based on the Phase 3 HELIOS-B trial, which met all 10 pre-specified primary and secondary endpoints.
In the overall population, AMVUTTRA reduced the risk of all-cause mortality and recurrent cardiovascular events by 28%a over up to 36 months of double-blind treatment, and reduced mortality by 36% through 42 months in a secondary analysis. The monotherapy subgroup showed a 33% risk reduction in the double-blind period and a 35% mortality reduction through 42 months. The company reported no new safety concerns in HELIOS-B; the safety profile is drawn from the hATTR-PN experience, with the most common adverse reactions being pain in extremity (15%), arthralgia (11%), dyspnea (7%), and decreased vitamin A (7%).
The label requires vitamin A supplementation at the recommended daily allowance. For investors, the key considerations are commercial execution and payer dynamics. Management expects broad coverage and mostly $0b out-of-pocket costs for ATTR-CM patients, based on the ~99% insurer coverage and majority $0 out-of-pocket experience in hATTR-PN.
Marketing applications based on HELIOS-B are under review at the EMA, ANVISA, and PMDA, with additional global submissions planned for 2025. This filing is an Item 8.01 disclosure of the press release, and it contains no financial statements or quantitative financial guidance.
02—Key points
Key Highlights
- FDA approved the sNDA for AMVUTTRA (vutrisiran) for ATTR-CM in adults, reducing cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.
- AMVUTTRA is now the first and only FDA-approved therapy for both ATTR-CM and hATTR polyneuropathy, expanding the U.S. label and addressable market.
- HELIOS-B Phase 3 trial met all 10 pre-specified primary and secondary endpoints, with a 28% reduction in all-cause mortality and recurrent CV events (overall population) and a 36% mortality reduction through 42 months.
- Management reports no new safety concerns in HELIOS-B; the most common adverse reactions in the hATTR-PN study were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and decreased vitamin A (7%).
- Management expects broad payer coverage (~99% in hATTR-PN) and mostly $0 out-of-pocket costs for ATTR-CM, supported by the Alnylam Assist patient support program.
- Marketing applications based on HELIOS-B are under review at the EMA, ANVISA, and PMDA, with additional global regulatory submissions planned for 2025.
- The filing is a disclosure under Item 8.01 with no financial statements or quantitative guidance, so the financial impact must be assessed from the company's future reporting.
03—Questions
Frequently Asked Questions
What did the FDA approve on March 20, 2025?
The FDA approved Alnylam's supplemental New Drug Application for AMVUTTRA (vutrisiran) to treat the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.
What clinical evidence supports the approval?
The approval is based on the Phase 3 HELIOS-B trial, which achieved statistical significance versus placebo on all 10 pre-specified primary and secondary endpoints. Overall, AMVUTTRA reduced all-cause mortality and recurrent CV events by 28% over up to 36 months of double-blind treatment, and mortality by 36% through 42 months in a secondary analysis. The results were published in The New England Journal of Medicine.
How large is the market opportunity?
Alnylam estimates ATTR-CM affects approximately 150,000 people in the U.S. and over 300,000 worldwide. The company states that most patients remain undiagnosed and untreated, which suggests a significant opportunity if diagnosis and treatment rates improve. The filing does not provide revenue forecasts or market-share estimates.
What are the main safety considerations?
The company reports no new safety concerns in HELIOS-B. The label is based on the hATTR-PN experience, where the most common adverse reactions were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and decreased vitamin A (7%). AMVUTTRA lowers serum vitamin A, so patients should take vitamin A at the recommended daily allowance, and patients with ocular symptoms of deficiency should be referred to an ophthalmologist.
What are the next regulatory and commercial steps?
Marketing applications based on HELIOS-B are under review by the EMA, ANVISA (Brazil), and PMDA (Japan). Alnylam plans additional global regulatory submissions for vutrisiran in 2025. On the commercial side, the company expects broad coverage and mostly $0 out-of-pocket costs for ATTR-CM patients, supported by its Alnylam Assist program.
04—Continue